| Royal, Mike |
NCT04905836: Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Treatment of COVID-19 Acute Respiratory Distress |
|
|
| Recruiting | 2 | 60 | US | COVI-MSC, Placebo | Sorrento Therapeutics, Inc. | Covid19 | 12/22 | 03/23 | | |
NCT04885972: Study to Evaluate Intra-articular Resiniferatoxin to Treat Moderate to Severe Pain From Knee Osteoarthritis |
|
|
| Active, not recruiting | 2 | 124 | US | Resiniferatoxin, RTX, Zilretta, triamcinolone acetonide, Placebo | Sorrento Therapeutics, Inc. | Osteoarthritis, Knee, Knee Osteoarthritis, Knee Pain Chronic | 09/23 | 11/23 | | |
NCT05067257: Study to Assess Epidural Resiniferatoxin for the Treatment of Intractable Pain Associated With Advanced Cancer |
|
|
| Suspended | 2 | 120 | US | Resiniferatoxin, RTX, Placebo | Sorrento Therapeutics, Inc. | Pain, Intractable, Pain Cancer, Pain | 06/27 | 12/27 | | |
NCT04992247: Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells to Treat Post COVID-19 "Long Haul" Pulmonary Compromise |
|
|
| Withdrawn | 2 | 60 | NA | COVI-MSC, Placebo | Sorrento Therapeutics, Inc. | Covid19 | 07/24 | 09/24 | | |
Maverick, NCT05361915: Study to Assess Abivertinib in Combination With Abiraterone in Metastatic Castration Resistant Prostate Cancer |
|
|
| Suspended | 2 | 100 | US | Abivertinib, STI-5656, Abiraterone | Sorrento Therapeutics, Inc. | Prostate Cancer, Prostate Cancer Metastatic | 01/28 | 01/28 | | |
NCT04559412: Study to Assess the Safety and Efficacy of Enbrel Administered by Sofusa DoseConnect for Rheumatoid Arthritis |
|
|
| Active, not recruiting | 1b | 11 | US | Sofusa DoseConnect, sofusa, Enbrel | Sorrento Therapeutics, Inc. | Rheumatoid Arthritis | 01/24 | 12/24 | | |
NCT05007418: Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory Multiple Myeloma |
|
|
| Recruiting | 1b | 54 | US | STI-1492 | Sorrento Therapeutics, Inc. | Multiple Myeloma | 12/25 | 02/26 | | |
OV2-RRST-101, NCT05361954: Study to Assess the Safety and Preliminary Efficacy of STI-1386 Oncolytic Virus in Relapsed or Refractory Solid Tumors |
|
|
| Not yet recruiting | 1b | 36 | NA | STI-1386, Seprehvec | Sorrento Therapeutics, Inc. | Cancer, Cancer of Pancreas, Sarcoma, Hepatic Metastasis, Solid Tumor | 10/26 | 02/27 | | |
NCT04900519: Study of the Safety and Efficacy of STI-6643 in Subjects With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 100 | US | STI-6643 | Sorrento Therapeutics, Inc. | Solid Tumor, Relapsed Solid Neoplasm, Refractory Tumor | 12/24 | 03/25 | | |
NCT05472649: Long-Term Follow-Up of Patients Who Received Gene-Modified Cell Therapy |
|
|
| Enrolling by invitation | N/A | 1 | US | Gene-Modified Cell Therapy | Sorrento Therapeutics, Inc. | Long-term Follow-up | 12/36 | 05/37 | | |
| Laird, Steve |
| No trials found |
